{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:15:49Z","timestamp":1794060949315,"version":"4.8.0"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82425003"],"award-info":[{"award-number":["No. 82425003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01759-2","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T01:19:55Z","timestamp":1763601595000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["In vivo CAR cell therapy: from bench to bedside"],"prefix":"10.1186","volume":"18","author":[{"given":"Jia","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaozhao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liman","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"issue":"3","key":"1759_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185\u201399. https:\/\/doi.org\/10.1038\/s41573-019-0051-2.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1759_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan K, Farrukh H, Chittepu VCSR, Xu H, Pan C-X, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41(1):119. https:\/\/doi.org\/10.1186\/s13046-022-02327-z.","journal-title":"J Exp Clin Cancer Res"},{"issue":"15","key":"1759_CR3","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","volume":"185","author":"A Raguram","year":"2022","unstructured":"Raguram A, Banskota S, Liu DR. Therapeutic in vivo delivery of gene editing agents. Cell. 2022;185(15):2806\u201327. https:\/\/doi.org\/10.1016\/j.cell.2022.03.045.","journal-title":"Cell"},{"issue":"11","key":"1759_CR4","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1016\/j.ymthe.2024.09.019","volume":"32","author":"Z Chen","year":"2024","unstructured":"Chen Z, Shu J, Hu Y, Mei H. Synergistic integration of mRNA-LNP with CAR-engineered immune cells: pioneering progress in immunotherapy. Mol Ther. 2024;32(11):3772\u201392. https:\/\/doi.org\/10.1016\/j.ymthe.2024.09.019.","journal-title":"Mol Ther"},{"key":"1759_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2024.114340","volume":"200","author":"D Stadler","year":"2024","unstructured":"Stadler D, Helbig C, Wuchner K, et al. Challenges in the analysis of pharmaceutical lentiviral vector products by orthogonal and complementary physical (nano)particle characterization techniques. Eur J Pharm Biopharm. 2024;200:114340. https:\/\/doi.org\/10.1016\/j.ejpb.2024.114340.","journal-title":"Eur J Pharm Biopharm"},{"key":"1759_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","volume":"8","author":"P Colella","year":"2018","unstructured":"Colella P, Ronzitti G, Mingozzi F. Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther. 2018;8:87. https:\/\/doi.org\/10.1016\/j.omtm.2017.11.007.","journal-title":"Mol Ther"},{"issue":"7","key":"1759_CR7","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","volume":"32","author":"MC Milone","year":"2018","unstructured":"Milone MC, O\u2019Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018;32(7):1529\u201341. https:\/\/doi.org\/10.1038\/s41375-018-0106-0.","journal-title":"Leukemia"},{"key":"1759_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2024.07.017","author":"Z Chen","year":"2024","unstructured":"Chen Z, Hu Y, Mei H. Harmonizing the symphony of chimeric antigen receptor T cell immunotherapy with the elegance of biomaterials. Trends Biotechnol. 2024. https:\/\/doi.org\/10.1016\/j.tibtech.2024.07.017.","journal-title":"Trends Biotechnol"},{"issue":"6","key":"1759_CR9","doi-asserted-by":"publisher","first-page":"474","DOI":"10.2174\/156652310793797748","volume":"10","author":"M Schweizer","year":"2010","unstructured":"Schweizer M, Merten OW. Large-scale production means for the manufacturing of lentiviral vectors. Curr Gene Ther. 2010;10(6):474\u201386. https:\/\/doi.org\/10.2174\/156652310793797748.","journal-title":"Curr Gene Ther"},{"issue":"18","key":"1759_CR10","doi-asserted-by":"publisher","first-page":"7306","DOI":"10.1073\/pnas.1214441110","volume":"110","author":"D Finkelshtein","year":"2013","unstructured":"Finkelshtein D, Werman A, Novick D, Barak S, Rubinstein M. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci U S A. 2013;110(18):7306\u201311. https:\/\/doi.org\/10.1073\/pnas.1214441110.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5813","key":"1759_CR11","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1126\/science.1135710","volume":"315","author":"S Roche","year":"2007","unstructured":"Roche S, Rey FA, Gaudin Y, Bressanelli S. Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G. Science. 2007;315(5813):843\u20138.","journal-title":"Science"},{"issue":"5784","key":"1759_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1126\/science.1127683","volume":"313","author":"S Roche","year":"2006","unstructured":"Roche S, Bressanelli S, Rey FA, Gaudin Y. Crystal structure of the low-pH form of the vesicular stomatitis virus glycoprotein G. Science. 2006;313(5784):187\u201391.","journal-title":"Science"},{"issue":"1","key":"1759_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03432-4","volume":"9","author":"J Nikolic","year":"2018","unstructured":"Nikolic J, Belot L, Raux H, Legrand P, Gaudin Y, A Albertini A. Structural basis for the recognition of LDL-receptor family members by VSV glycoprotein. Nat Commun. 2018;9(1):1029. https:\/\/doi.org\/10.1038\/s41467-018-03432-4.","journal-title":"Nat Commun"},{"issue":"1","key":"1759_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40788-8","volume":"14","author":"D Strebinger","year":"2023","unstructured":"Strebinger D, Frangieh CJ, Friedrich MJ, Faure G, Macrae RK, Zhang F. Cell type-specific delivery by modular envelope design. Nat Commun. 2023;14(1):5141. https:\/\/doi.org\/10.1038\/s41467-023-40788-8.","journal-title":"Nat Commun"},{"key":"1759_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.06.036","author":"JI Andorko","year":"2025","unstructured":"Andorko JI, Russell RM, Schnepp BC, et al. Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation. Mol Ther. 2025. https:\/\/doi.org\/10.1016\/j.ymthe.2025.06.036.","journal-title":"Mol Ther"},{"key":"1759_CR16","doi-asserted-by":"crossref","unstructured":"Bastien D, Melissa D, Alexia F et al. Engineering T cell-specific lentiviral vectors for safe and effective in vivo CAR-T therapy. ASGCT Annual Meeting Abstract. 2025;879.\u00a0https:\/\/doi.org\/https:\/\/www.sciencedirect.com\/journal\/molecular-therapy\/vol\/33\/issue\/4\/suppl\/S1","DOI":"10.1016\/j.ymthe.2025.04.028"},{"issue":"8","key":"1759_CR17","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/gt.2013.1","volume":"20","author":"BY Hwang","year":"2013","unstructured":"Hwang BY, Schaffer DV. Engineering a serum-resistant and thermostable vesicular stomatitis virus G glycoprotein for pseudotyping retroviral and lentiviral vectors. Gene Ther. 2013;20(8):807\u201315. https:\/\/doi.org\/10.1038\/gt.2013.1.","journal-title":"Gene Ther"},{"issue":"Supplement 1","key":"1759_CR18","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1182\/blood-2024-211267","volume":"144","author":"S Amatya","year":"2024","unstructured":"Amatya S, Green J, Chu C-S, et al. Enabling potent T cell delivery and mitigating key off-target concerns of in vivo CAR T lentiviral vectors with the targeted paramyxovirus fusogen system. Blood. 2024;144(Supplement 1):2047. https:\/\/doi.org\/10.1182\/blood-2024-211267.","journal-title":"Blood"},{"issue":"8","key":"1759_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.tim.2011.03.005","volume":"19","author":"B Lee","year":"2011","unstructured":"Lee B, Ataman ZA. Modes of paramyxovirus fusion: a henipavirus perspective. Trends Microbiol. 2011;19(8):389\u201399. https:\/\/doi.org\/10.1016\/j.tim.2011.03.005.","journal-title":"Trends Microbiol"},{"issue":"6","key":"1759_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005641","volume":"12","author":"RR Bender","year":"2016","unstructured":"Bender RR, Muth A, Schneider IC, et al. Receptor-targeted Nipah virus glycoproteins improve cell-type selective gene delivery and reveal a preference for membrane-proximal cell attachment. PLoS Pathog. 2016;12(6):e1005641. https:\/\/doi.org\/10.1371\/journal.ppat.1005641.","journal-title":"PLoS Pathog"},{"issue":"7049","key":"1759_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nature03838","volume":"436","author":"OA Negrete","year":"2005","unstructured":"Negrete OA, Levroney EL, Aguilar HC, et al. EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature. 2005;436(7049):401\u20135.","journal-title":"Nature"},{"key":"1759_CR22","doi-asserted-by":"publisher","unstructured":"Witting SR, Vallanda P, Gamble AL. Characterization of a third generation lentiviral vector pseudotyped with Nipah virus envelope proteins for endothelial cell transduction. Gene Ther. 2013;1005. https:\/\/doi.org\/10.1038\/gt.2013.23.","DOI":"10.1038\/gt.2013.23"},{"key":"1759_CR23","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809158","author":"A Pfeiffer","year":"2018","unstructured":"Pfeiffer A, Thalheimer FB, Hartmann S, et al. In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome. EMBO Mol Med. 2018. https:\/\/doi.org\/10.15252\/emmm.201809158.","journal-title":"EMBO Mol Med"},{"issue":"12","key":"1759_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1671761","volume":"8","author":"S Agarwal","year":"2019","unstructured":"Agarwal S, Weidner T, Thalheimer FB, Buchholz CJ. In vivo generated human CAR T cells eradicate tumor cells. Oncoimmunology. 2019;8(12):e1671761. https:\/\/doi.org\/10.1080\/2162402X.2019.1671761.","journal-title":"Oncoimmunology"},{"issue":"22","key":"1759_CR25","doi-asserted-by":"publisher","first-page":"5702","DOI":"10.1182\/bloodadvances.2020002229","volume":"4","author":"AM Frank","year":"2020","unstructured":"Frank AM, Braun AH, Scheib L, et al. Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors. Blood Adv. 2020;4(22):5702\u201315. https:\/\/doi.org\/10.1182\/bloodadvances.2020002229.","journal-title":"Blood Adv"},{"issue":"8","key":"1759_CR26","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1038\/mt.2008.128","volume":"16","author":"S Funke","year":"2008","unstructured":"Funke S, Maisner A, M\u00fchlebach MD, et al. Targeted cell entry of lentiviral vectors. Mol Ther. 2008;16(8):1427\u201336. https:\/\/doi.org\/10.1038\/mt.2008.128.","journal-title":"Mol Ther"},{"issue":"10","key":"1759_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046667","volume":"7","author":"S Kneissl","year":"2012","unstructured":"Kneissl S, Abel T, Rasbach A, Brynza J, Schneider-Schaulies J, Buchholz CJ. Measles virus glycoprotein-based lentiviral targeting vectors that avoid neutralizing antibodies. PLoS ONE. 2012;7(10):e46667. https:\/\/doi.org\/10.1371\/journal.pone.0046667.","journal-title":"PLoS ONE"},{"issue":"9","key":"1759_CR28","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1038\/mt.2012.96","volume":"20","author":"C L\u00e9vy","year":"2012","unstructured":"L\u00e9vy C, Amirache F, Costa C, et al. Lentiviral vectors displaying modified measles virus Gp overcome pre-existing immunity in in vivo-like transduction of human T and B cells. Mol Ther. 2012;20(9):1699\u2013712. https:\/\/doi.org\/10.1038\/mt.2012.96.","journal-title":"Mol Ther"},{"issue":"5","key":"1759_CR29","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.4049\/jimmunol.1500956","volume":"195","author":"Q Zhou","year":"2015","unstructured":"Zhou Q, Uhlig KM, Muth A, et al. Exclusive transduction of human CD4\u2009+\u2009T cells upon systemic delivery of CD4-targeted lentiviral vectors. J Immunol. 2015;195(5):2493\u2013501. https:\/\/doi.org\/10.4049\/jimmunol.1500956.","journal-title":"J Immunol"},{"issue":"8","key":"1759_CR30","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","volume":"28","author":"S Agarwal","year":"2020","unstructured":"Agarwal S, Hanauer JDS, Frank AM, Riechert V, Thalheimer FB, Buchholz CJ. In vivo generation of CAR T cells selectively in human CD4\u2009+\u2009lymphocytes. Mol Ther. 2020;28(8):1783\u201394. https:\/\/doi.org\/10.1016\/j.ymthe.2020.05.005.","journal-title":"Mol Ther"},{"key":"1759_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.omtm.2018.10.006","volume":"12","author":"AM Frank","year":"2019","unstructured":"Frank AM, Buchholz CJ. Surface-engineered lentiviral vectors for selective gene transfer into subtypes of lymphocytes. Mol Ther. 2019;12:19\u201331. https:\/\/doi.org\/10.1016\/j.omtm.2018.10.006.","journal-title":"Mol Ther"},{"key":"1759_CR32","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.omtm.2022.06.004","volume":"26","author":"N Ho","year":"2022","unstructured":"Ho N, Agarwal S, Milani M, Cantore A, Buchholz CJ, Thalheimer FB. In vivo generation of CAR T cells in the presence of human myeloid cells. Mol Ther. 2022;26:144\u201356. https:\/\/doi.org\/10.1016\/j.omtm.2022.06.004.","journal-title":"Mol Ther"},{"issue":"3","key":"1759_CR33","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nm1192","volume":"11","author":"K Morizono","year":"2005","unstructured":"Morizono K, Xie Y, Ringpis G-E, et al. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med. 2005;11(3):346\u201352.","journal-title":"Nat Med"},{"key":"1759_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002737","author":"JT Huckaby","year":"2021","unstructured":"Huckaby JT, Landoni E, Jacobs TM, Savoldo B, Dotti G, Lai SK. Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-002737.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"1759_CR35","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1182\/blood.2024024523","volume":"144","author":"CJ Nicolai","year":"2024","unstructured":"Nicolai CJ, Parker MH, Qin J, et al. In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand. Blood. 2024;144(9):977\u201387. https:\/\/doi.org\/10.1182\/blood.2024024523.","journal-title":"Blood"},{"key":"1759_CR36","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1182\/blood-2023-189087","volume":"142","author":"JI Andorko","year":"2023","unstructured":"Andorko JI, Russell RM, Schnepp BC. Targeted in vivo generation of CAR T and NK cells utilizing an engineered lentiviral vector platform. Blood. 2023;142:763. https:\/\/doi.org\/10.1182\/blood-2023-189087.","journal-title":"Blood"},{"issue":"10","key":"1759_CR37","first-page":"983","volume":"11","author":"HS Khalidi","year":"1998","unstructured":"Khalidi HS, Brynes RK, Browne P, Koo CH, Battifora H, Medeiros LJ. Intravascular large B-cell lymphoma: the CD5 antigen is expressed by a subset of cases. Mod Pathol. 1998;11(10):983\u20138.","journal-title":"Mod Pathol"},{"issue":"11","key":"1759_CR38","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41571-019-0239-8","volume":"16","author":"F Bosch","year":"2019","unstructured":"Bosch F, Dalla-Favera R. Chronic lymphocytic leukaemia: from genetics to treatment. Nat Rev Clin Oncol. 2019;16(11):684\u2013701. https:\/\/doi.org\/10.1038\/s41571-019-0239-8.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"1759_CR39","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/s41587-023-02085-z","volume":"42","author":"JR Hamilton","year":"2024","unstructured":"Hamilton JR, Chen E, Perez BS, et al. In vivo human T cell engineering with enveloped delivery vehicles. Nat Biotechnol. 2024;42(11):1684\u201392. https:\/\/doi.org\/10.1038\/s41587-023-02085-z.","journal-title":"Nat Biotechnol"},{"issue":"11\u201312","key":"1759_CR40","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1089\/hum.2019.248","volume":"31","author":"AM Frank","year":"2020","unstructured":"Frank AM, Weidner T, Brynza J, Uckert W, Buchholz CJ, Hartmann J. CD8-Specific designed Ankyrin repeat proteins improve selective gene delivery into human and primate T lymphocytes. Hum Gene Ther. 2020;31(11\u201312):679\u201391. https:\/\/doi.org\/10.1089\/hum.2019.248.","journal-title":"Hum Gene Ther"},{"key":"1759_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.07.006","author":"T Coradin","year":"2025","unstructured":"Coradin T, Keating AL, Barnard AR, et al. Efficient in vivo generation of CAR T cells using a retargeted 4th generation lentiviral vector. Mol Ther. 2025. https:\/\/doi.org\/10.1016\/j.ymthe.2025.07.006.","journal-title":"Mol Ther"},{"issue":"10","key":"1759_CR42","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1016\/j.ymthe.2024.08.002","volume":"32","author":"MB Demircan","year":"2024","unstructured":"Demircan MB, Zinser LJ, Michels A, et al. T-cell specific in vivo gene delivery with DART-AAVs targeted to CD8. Mol Ther. 2024;32(10):3470\u201384. https:\/\/doi.org\/10.1016\/j.ymthe.2024.08.002.","journal-title":"Mol Ther"},{"issue":"5","key":"1759_CR43","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/j.ymthe.2025.03.064","volume":"33","author":"L Suarez-Amaran","year":"2025","unstructured":"Suarez-Amaran L, Song L, Tretiakova AP, Mikhail SA, Samulski RJ. AAV vector development, back to the future. Mol Ther. 2025;33(5):1903\u201336. https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.064.","journal-title":"Mol Ther"},{"issue":"12","key":"1759_CR44","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1016\/j.ymthe.2022.09.015","volume":"30","author":"A Pupo","year":"2022","unstructured":"Pupo A, Fern\u00e1ndez A, Low SH, Fran\u00e7ois A, Su\u00e1rez-Amar\u00e1n L, Samulski RJ. AAV vectors: the rubik\u2019s cube of human gene therapy. Mol Ther. 2022;30(12):3515\u201341. https:\/\/doi.org\/10.1016\/j.ymthe.2022.09.015.","journal-title":"Mol Ther"},{"key":"1759_CR45","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","volume":"74","author":"BJ Samelson-Jones","year":"2023","unstructured":"Samelson-Jones BJ, George LA. Adeno-associated virus gene therapy for hemophilia. Annu Rev Med. 2023;74:231\u201347. https:\/\/doi.org\/10.1146\/annurev-med-043021-033013.","journal-title":"Annu Rev Med"},{"key":"1759_CR46","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jconrel.2016.01.001","volume":"240","author":"JL Santiago-Ortiz","year":"2016","unstructured":"Santiago-Ortiz JL, Schaffer DV. Adeno-associated virus (AAV) vectors in cancer gene therapy. J Control Release. 2016;240:287\u2013301. https:\/\/doi.org\/10.1016\/j.jconrel.2016.01.001.","journal-title":"J Control Release"},{"key":"1759_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.029","author":"M Pouzolles","year":"2020","unstructured":"Pouzolles M, Machado A, Guilbaud M, et al. Intrathymic adeno-associated virus gene transfer rapidly restores thymic function and long-term persistence of gene-corrected T cells. J Allergy Clin Immunol. 2020. https:\/\/doi.org\/10.1016\/j.jaci.2019.08.029.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1759_CR48","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/mt.2008.272","volume":"17","author":"A Moreau","year":"2009","unstructured":"Moreau A, Vicente R, Dubreil L, et al. Efficient intrathymic gene transfer following in situ administration of a rAAV serotype 8 vector in mice and nonhuman primates. Mol Ther. 2009;17(3):472\u20139. https:\/\/doi.org\/10.1038\/mt.2008.272.","journal-title":"Mol Ther"},{"issue":"19","key":"1759_CR49","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1182\/blood.2022017378","volume":"141","author":"A Calabria","year":"2023","unstructured":"Calabria A, Cipriani C, Spinozzi G, et al. Intrathymic AAV delivery results in therapeutic site-specific integration at TCR loci in mice. Blood. 2023;141(19):2316\u201329. https:\/\/doi.org\/10.1182\/blood.2022017378.","journal-title":"Blood"},{"issue":"1","key":"1759_CR50","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/mt.2012.186","volume":"21","author":"RC M\u00fcnch","year":"2013","unstructured":"M\u00fcnch RC, Janicki H, V\u00f6lker I, et al. Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol Ther. 2013;21(1):109\u201318. https:\/\/doi.org\/10.1038\/mt.2012.186.","journal-title":"Mol Ther"},{"issue":"18","key":"1759_CR51","doi-asserted-by":"publisher","first-page":"8635","DOI":"10.1128\/JVI.74.18.8635-8647.2000","volume":"74","author":"P Wu","year":"2000","unstructured":"Wu P, Xiao W, Conlon T, et al. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol. 2000;74(18):8635\u201347.","journal-title":"J Virol"},{"issue":"24","key":"1759_CR52","doi-asserted-by":"publisher","first-page":"12945","DOI":"10.1128\/JVI.01235-10","volume":"84","author":"R Ng","year":"2010","unstructured":"Ng R, Govindasamy L, Gurda BL, et al. Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J Virol. 2010;84(24):12945\u201357. https:\/\/doi.org\/10.1128\/JVI.01235-10.","journal-title":"J Virol"},{"issue":"11","key":"1759_CR53","doi-asserted-by":"publisher","first-page":"5219","DOI":"10.1128\/JVI.00161-16","volume":"90","author":"L-Y Huang","year":"2016","unstructured":"Huang L-Y, Patel A, Ng R, et al. Characterization of the adeno-associated virus 1 and 6 sialic acid binding site. J Virol. 2016;90(11):5219\u201330. https:\/\/doi.org\/10.1128\/JVI.00161-16.","journal-title":"J Virol"},{"issue":"11","key":"1759_CR54","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1038\/mtna.2012.46","volume":"1","author":"J Judd","year":"2012","unstructured":"Judd J, Wei F, Nguyen PQ, et al. Random insertion of mCherry into VP3 domain of Adeno-associated virus yields fluorescent capsids with no loss of infectivity. Mol Ther Nucleic Acids. 2012;1(11):e54. https:\/\/doi.org\/10.1038\/mtna.2012.46.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1759_CR55","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.omtm.2019.09.003","volume":"15","author":"AM Eichhoff","year":"2019","unstructured":"Eichhoff AM, B\u00f6rner K, Albrecht B, et al. Nanobody-enhanced targeting of AAV gene therapy vectors. Mol Ther. 2019;15:211\u201320. https:\/\/doi.org\/10.1016\/j.omtm.2019.09.003.","journal-title":"Mol Ther"},{"issue":"6","key":"1759_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00508-1","volume":"11","author":"W Nawaz","year":"2021","unstructured":"Nawaz W, Huang B, Xu S, et al. AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia. Blood Cancer J. 2021;11(6):119. https:\/\/doi.org\/10.1038\/s41408-021-00508-1.","journal-title":"Blood Cancer J"},{"key":"1759_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.12.022","author":"WA Nyberg","year":"2023","unstructured":"Nyberg WA, Ark J, To A, et al. An evolved AAV variant enables efficient genetic engineering of murine T cells. Cell. 2023. https:\/\/doi.org\/10.1016\/j.cell.2022.12.022.","journal-title":"Cell"},{"key":"1759_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2025.01.009","author":"WA Nyberg","year":"2025","unstructured":"Nyberg WA, Wang CH, Ark J, et al. In vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313. Immunity. 2025. https:\/\/doi.org\/10.1016\/j.immuni.2025.01.009.","journal-title":"Immunity"},{"key":"1759_CR59","doi-asserted-by":"crossref","unstructured":"Shlomo M, Inbal Reuveni O, Miri H-F et al. In vivo site-specific T cell engineering allows complete remission of human leukemia in mice. ASGCT Annual Meeting Abstract. 2025;222.\u00a0https:\/\/doi.org\/https:\/\/doi.org\/https:\/\/www.sciencedirect.com\/journal\/molecular-therapy\/vol\/33\/issue\/4\/suppl\/S1","DOI":"10.1016\/j.ymthe.2025.04.028"},{"issue":"10","key":"1759_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202500029","volume":"26","author":"H Liu","year":"2025","unstructured":"Liu H, Su R, Qi W, Wang Y. Cationic polymers for gene delivery: properties and functional optimization. Chembiochem. 2025;26(10):e202500029. https:\/\/doi.org\/10.1002\/cbic.202500029.","journal-title":"Chembiochem"},{"issue":"21","key":"1759_CR61","doi-asserted-by":"publisher","first-page":"7147","DOI":"10.1039\/c2cs35094g","volume":"41","author":"SK Samal","year":"2012","unstructured":"Samal SK, Dash M, Van Vlierberghe S, et al. Cationic polymers and their therapeutic potential. Chem Soc Rev. 2012;41(21):7147\u201394. https:\/\/doi.org\/10.1039\/c2cs35094g.","journal-title":"Chem Soc Rev"},{"issue":"5","key":"1759_CR62","first-page":"568","volume":"29","author":"X Ren","year":"2013","unstructured":"Ren X, Yang L, Liang X, Liu Z, Deng Y. Advances in cationic polymers used as nonviral vectors for gene delivery. Sheng Wu Gong Cheng Xue Bao. 2013;29(5):568\u201377.","journal-title":"Sheng Wu Gong Cheng Xue Bao"},{"issue":"11","key":"1759_CR63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2307800120","volume":"121","author":"S Chatterjee","year":"2024","unstructured":"Chatterjee S, Kon E, Sharma P, Peer D. Endosomal escape: a bottleneck for LNP-mediated therapeutics. Proc Natl Acad Sci U S A. 2024;121(11):e2307800120. https:\/\/doi.org\/10.1073\/pnas.2307800120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1759_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29133131","author":"N Desai","year":"2024","unstructured":"Desai N, Rana D, Salave S, Benival D, Khunt D, Prajapati BG. Achieving endo\/lysosomal escape using smart nanosystems for efficient cellular delivery. Molecules. 2024. https:\/\/doi.org\/10.3390\/molecules29133131.","journal-title":"Molecules"},{"issue":"12","key":"1759_CR65","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1007\/s13346-024-01585-y","volume":"14","author":"JR Maga\u00f1a Rodriguez","year":"2024","unstructured":"Maga\u00f1a Rodriguez JR, Guerra-Rebollo M, Borr\u00f3s S, Fornaguera C. Nucleic acid-loaded poly(beta-aminoester) nanoparticles for cancer nano-immuno therapeutics: the good, the bad, and the future. Drug Deliv Transl Res. 2024;14(12):3477\u201393. https:\/\/doi.org\/10.1007\/s13346-024-01585-y.","journal-title":"Drug Deliv Transl Res"},{"key":"1759_CR66","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.jconrel.2023.05.017","volume":"358","author":"R Cosialls","year":"2023","unstructured":"Cosialls R, Fern\u00e1ndez O, Sim\u00f3 C, et al. Ammonium trifluoroborate-modified poly(\u03b2-aminoesters): A case study for PET-guided in vivo pharmacokinetic studies of a non-viral gene delivery system. J Control Release. 2023;358:739\u201351. https:\/\/doi.org\/10.1016\/j.jconrel.2023.05.017.","journal-title":"J Control Release"},{"issue":"8","key":"1759_CR67","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nnano.2017.57","volume":"12","author":"TT Smith","year":"2017","unstructured":"Smith TT, Stephan SB, Moffett HF, et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat Nanotechnol. 2017;12(8):813\u201320. https:\/\/doi.org\/10.1038\/nnano.2017.57.","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"1759_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19486-2","volume":"11","author":"NN Parayath","year":"2020","unstructured":"Parayath NN, Stephan SB, Koehne AL, Nelson PS, Stephan MT. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat Commun. 2020;11(1):6080. https:\/\/doi.org\/10.1038\/s41467-020-19486-2.","journal-title":"Nat Commun"},{"key":"1759_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.783305","volume":"12","author":"C Sloas","year":"2021","unstructured":"Sloas C, Gill S, Klichinsky M. Engineered CAR-macrophages as adoptive immunotherapies for solid tumors. Front Immunol. 2021;12:783305. https:\/\/doi.org\/10.3389\/fimmu.2021.783305.","journal-title":"Front Immunol"},{"issue":"1","key":"1759_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-01810-9","volume":"21","author":"L Gao","year":"2023","unstructured":"Gao L, Shi C, Yang Z, et al. Convection-enhanced delivery of nanoencapsulated gene locoregionally yielding ErbB2\/Her2-specific CAR-macrophages for brainstem glioma immunotherapy. J Nanobiotechnol. 2023;21(1):56. https:\/\/doi.org\/10.1186\/s12951-023-01810-9.","journal-title":"J Nanobiotechnol"},{"key":"1759_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/s0065-2660(05)53008-6","author":"B Demeneix","year":"2005","unstructured":"Demeneix B, Behr JP. Polyethylenimine (PEI). Adv Genet. 2005. https:\/\/doi.org\/10.1016\/s0065-2660(05)53008-6.","journal-title":"Adv Genet"},{"issue":"43","key":"1759_CR72","doi-asserted-by":"publisher","first-page":"e2103258","DOI":"10.1002\/adma.202103258","volume":"33","author":"M Kang","year":"2021","unstructured":"Kang M, Lee SH, Kwon M, et al. Nanocomplex-Mediated in vivo programming to chimeric antigen Receptor-M1 macrophages for cancer therapy. Adv Mater. 2021;33(43):e2103258. https:\/\/doi.org\/10.1002\/adma.202103258.","journal-title":"Adv Mater"},{"key":"1759_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25235672","author":"B Almeida","year":"2020","unstructured":"Almeida B, Nag OK, Rogers KE, Delehanty JB. Recent progress in bioconjugation strategies for liposome-mediated drug delivery. Molecules. 2020. https:\/\/doi.org\/10.3390\/molecules25235672.","journal-title":"Molecules"},{"issue":"1","key":"1759_CR74","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/08982104.2023.2226216","volume":"34","author":"H Nsairat","year":"2024","unstructured":"Nsairat H, Ibrahim AA, Jaber AM, et al. Liposome bilayer stability: emphasis on cholesterol and its alternatives. J Liposome Res. 2024;34(1):178\u2013202. https:\/\/doi.org\/10.1080\/08982104.2023.2226216.","journal-title":"J Liposome Res"},{"key":"1759_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2023.101805","volume":"49","author":"Y Liu","year":"2023","unstructured":"Liu Y, Jing W, Zhang J. In situ MUC1-specific CAR engineering of tumor-supportive macrophages stimulates tumoricidal immunity against pancreatic adenocarcinoma. Nano Today. 2023;49:101805. https:\/\/doi.org\/10.1016\/j.nantod.2023.101805.","journal-title":"Nano Today"},{"key":"1759_CR76","unstructured":"Jingwei S, Xi Z, Zhongzheng C et al. In vivo mRNA CAR-T Cell Engineering Utilizing a Novel CD3\/CD5 Peptide Based Targeted Nanoparticles. ASGCT Annual Meeting Abstract. 2025;1283.\u00a0https:\/\/doi.org\/https:\/\/doi.org\/https:\/\/www.sciencedirect.com\/journal\/molecular-therapy\/vol\/33\/issue\/4\/suppl\/S1"},{"issue":"22","key":"1759_CR77","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg3365","volume":"9","author":"Z Li","year":"2023","unstructured":"Li Z, Zhang S, Fu Z, et al. Surficial nano-deposition locoregionally yielding bactericidal super CAR-macrophages expedites periprosthetic osseointegration. Sci Adv. 2023;9(22):eadg3365. https:\/\/doi.org\/10.1126\/sciadv.adg3365.","journal-title":"Sci Adv"},{"issue":"51","key":"1759_CR78","doi-asserted-by":"publisher","first-page":"e2303261","DOI":"10.1002\/adma.202303261","volume":"35","author":"Y Zong","year":"2023","unstructured":"Zong Y, Lin Y, Wei T, Cheng Q. Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy. Adv Mater. 2023;35(51):e2303261. https:\/\/doi.org\/10.1002\/adma.202303261.","journal-title":"Adv Mater"},{"key":"1759_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1336906","volume":"15","author":"BZ Igy\u00e1rt\u00f3","year":"2024","unstructured":"Igy\u00e1rt\u00f3 BZ, Qin Z. The mRNA-LNP vaccines - the good, the bad and the ugly? Front Immunol. 2024;15:1336906. https:\/\/doi.org\/10.3389\/fimmu.2024.1336906.","journal-title":"Front Immunol"},{"issue":"11","key":"1759_CR80","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1016\/j.ymthe.2024.09.019","volume":"32","author":"Z Chen","year":"2024","unstructured":"Chen Z, Shu J, Hu Y, Mei H. Synergistic integration of mRNA-LNP with CAR-engineered immune cells: pioneering progress in immunotherapy. Mol Ther. 2024;32(11):3772\u201392. https:\/\/doi.org\/10.1016\/j.ymthe.2024.09.019.","journal-title":"Mol Ther"},{"issue":"17\u201318","key":"1759_CR81","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1089\/hum.2024.106","volume":"35","author":"N Saber","year":"2024","unstructured":"Saber N, Senti ME, Schiffelers RM. Lipid nanoparticles for nucleic acid delivery beyond the liver. Hum Gene Ther. 2024;35(17\u201318):617\u201327. https:\/\/doi.org\/10.1089\/hum.2024.106.","journal-title":"Hum Gene Ther"},{"key":"1759_CR82","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jconrel.2022.08.033","volume":"350","author":"JE Zhou","year":"2022","unstructured":"Zhou JE, Sun L, Jia Y, et al. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo. J Control Release. 2022;350:298\u2013307. https:\/\/doi.org\/10.1016\/j.jconrel.2022.08.033.","journal-title":"J Control Release"},{"key":"1759_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2024.102518","volume":"59","author":"Y Li","year":"2024","unstructured":"Li Y, Tian Y, Li C, et al. In situ engineering of mRNA-CAR T cells using spleen-targeted ionizable lipid nanoparticles to eliminate cancer cells. Nano Today. 2024;59:102518. https:\/\/doi.org\/10.1016\/j.nantod.2024.102518.","journal-title":"Nano Today"},{"issue":"6753","key":"1759_CR84","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter TL, Bao Y, Zhang Y, et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science. 2025;388(6753):1311\u20137. https:\/\/doi.org\/10.1126\/science.ads8473.","journal-title":"Science"},{"key":"1759_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering10020122","author":"S Pirkalkhoran","year":"2023","unstructured":"Pirkalkhoran S, Grabowska WR, Kashkoli HH, et al. Bioengineering of antibody fragments: challenges and opportunities. Bioengineering. 2023. https:\/\/doi.org\/10.3390\/bioengineering10020122.","journal-title":"Bioengineering"},{"issue":"11","key":"1759_CR86","doi-asserted-by":"publisher","first-page":"e2304378","DOI":"10.1002\/smll.202304378","volume":"20","author":"MM Billingsley","year":"2024","unstructured":"Billingsley MM, Gong N, Mukalel AJ, et al. In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism. Small. 2024;20(11):e2304378. https:\/\/doi.org\/10.1002\/smll.202304378.","journal-title":"Small"},{"key":"1759_CR87","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011759","author":"JF Bimbo","year":"2025","unstructured":"Bimbo JF, van Diest E, Murphy DE, et al. T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2025-011759.","journal-title":"J Immunother Cancer"},{"key":"1759_CR88","unstructured":"Yan F, Weppler S, Wong TCG et al. Improved T Cell Delivery and Expression of mRNA Using CD8-Targeted Lipid Nanoparticles with Athebody\u00ae Designed Ankyrin Repeat Proteins (DARPins). ASGCT Annual Meeting Abstract .\u00a02025;667.\u00a0https:\/\/doi.org\/https:\/\/www.sciencedirect.com\/journal\/molecular-therapy\/vol\/33\/issue\/4\/suppl\/S1"},{"key":"1759_CR89","doi-asserted-by":"crossref","unstructured":"Jingwei Sun1, Zhu X2, Cao Z 3 et al. In Vivo CAR-T Therapy Powered by Novel CLAMP Technology for T cell-Targeted mRNA Delivery. ASGCT Annual Meeting Abstract.\u00a02025;1282.\u00a0https:\/\/doi.org\/https:\/\/www.sciencedirect.com\/journal\/molecular-therapy\/vol\/33\/issue\/4\/suppl\/S1","DOI":"10.1016\/j.ymthe.2025.04.028"},{"key":"1759_CR90","doi-asserted-by":"crossref","unstructured":"Minkyeom K, Dae-Hyuk KW. Park. Development of In Vivo CAR T Cell Therapy Using Nanoparticle and RNA-Based Gene Delivery Systems.\u00a0ASGCT Annual Meeting Abstract . 2025;796. https:\/\/doi.org\/https:\/\/www.sciencedirect.com\/journal\/molecular-therapy\/vol\/33\/issue\/4\/suppl\/S1","DOI":"10.1016\/j.ymthe.2025.04.028"},{"issue":"6576","key":"1759_CR91","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik JG, Tomb\u00e1cz I, Yadegari A, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375(6576):91\u20136. https:\/\/doi.org\/10.1126\/science.abm0594.","journal-title":"Science"},{"key":"1759_CR92","doi-asserted-by":"publisher","unstructured":"Liu Z, Chen C, Zhang Y, et al. Legumain In Situ Engineering Promotes Efferocytosis of CAR Macrophage to Treat Cardiac Fibrosis. Adv Mater. 2025;e2417831. https:\/\/doi.org\/10.1002\/adma.202417831.","DOI":"10.1002\/adma.202417831"},{"issue":"1","key":"1759_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59093-7","volume":"16","author":"J Yan","year":"2025","unstructured":"Yan J, Wang SY, Su Q, et al. Targeted immunotherapy rescues pulmonary fibrosis by reducing activated fibroblasts and regulating alveolar cell profile. Nat Commun. 2025;16(1):3748. https:\/\/doi.org\/10.1038\/s41467-025-59093-7.","journal-title":"Nat Commun"},{"key":"1759_CR94","doi-asserted-by":"publisher","unstructured":"Yashaswini CN, Cogliati B, Qin T et al. In vivo anti-FAP CAR T therapy reduces fibrosis and restores liver homeostasis in metabolic dysfunction-associated steatohepatitis. BioRxiv 2025.\u00a0https:\/\/doi.org\/10.1101\/2025.02.25.640143","DOI":"10.1101\/2025.02.25.640143"},{"key":"1759_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153570","author":"A Papait","year":"2022","unstructured":"Papait A, Romoli J, Stefani FR, et al. Fight the cancer, hit the CAF! Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14153570.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"1759_CR96","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41568-024-00740-4","volume":"24","author":"L Arpinati","year":"2024","unstructured":"Arpinati L, Carradori G, Scherz-Shouval R. CAF-induced physical constraints controlling T cell state and localization in solid tumours. Nat Rev Cancer. 2024;24(10):676\u201393. https:\/\/doi.org\/10.1038\/s41568-024-00740-4.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"1759_CR97","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat Rev Clin Oncol. 2020;17(9):527\u201340. https:\/\/doi.org\/10.1038\/s41571-020-0363-5.","journal-title":"Nat Rev Clin Oncol"},{"key":"1759_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113888","volume":"384","author":"W Wang","year":"2025","unstructured":"Wang W, Hu K, Xue J, et al. In vivo FAP-CAR macrophages enhance chemotherapy and immunotherapy against pancreatic cancer by removing the fibrosis barrier. J Control Release. 2025;384:113888. https:\/\/doi.org\/10.1016\/j.jconrel.2025.113888.","journal-title":"J Control Release"},{"key":"1759_CR99","doi-asserted-by":"crossref","unstructured":"Zhang S, Lu H, Zhang H et al. In vivo engineered quadrivalent CAR-macrophages break tumor barrier, remodel TME and overcome tumor heterogeneity through antigen spreading. BioRxiv 2024.","DOI":"10.1101\/2024.11.06.621821"},{"issue":"3","key":"1759_CR100","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1021\/acsnano.3c10109","volume":"18","author":"C Tang","year":"2024","unstructured":"Tang C, Jing W, Han K, et al. mRNA-laden lipid-nanoparticle-enabled in situ CAR-macrophage engineering for the eradication of multidrug-resistant bacteria in a sepsis mouse model. ACS Nano. 2024;18(3):2261\u201378. https:\/\/doi.org\/10.1021\/acsnano.3c10109.","journal-title":"ACS Nano"},{"issue":"1","key":"1759_CR101","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","volume":"18","author":"X Wang","year":"2023","unstructured":"Wang X, Liu S, Sun Y, et al. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat Protoc. 2023;18(1):265\u201391. https:\/\/doi.org\/10.1038\/s41596-022-00755-x.","journal-title":"Nat Protoc"},{"key":"1759_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-025-02675-z","author":"M Kim","year":"2025","unstructured":"Kim M, Song ES, Chen JC, et al. Dual SORT LNPs for multi-organ base editing. Nat Biotechnol. 2025. https:\/\/doi.org\/10.1038\/s41587-025-02675-z.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"1759_CR103","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol. 2020;15(4):313\u201320. https:\/\/doi.org\/10.1038\/s41565-020-0669-6.","journal-title":"Nat Nanotechnol"},{"issue":"44","key":"1759_CR104","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202310395","volume":"62","author":"E \u00c1lvarez-Benedicto","year":"2023","unstructured":"\u00c1lvarez-Benedicto E, Tian Z, Chatterjee S, et al. Spleen SORT LNP generated in situ CAR T cells extend survival in a mouse model of lymphoreplete B cell lymphoma. Angew Chem Int Ed Engl. 2023;62(44):e202310395. https:\/\/doi.org\/10.1002\/anie.202310395.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"8","key":"1759_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102250","volume":"6","author":"Y Wang","year":"2025","unstructured":"Wang Y, Lin L, Wang X, et al. Synergically enhanced anti-tumor immunity of in vivo PanCAR by circrna vaccine boosting. Cell Rep Med. 2025;102250. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102250.","journal-title":"Cell Rep Med"},{"issue":"7814","key":"1759_CR106","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","volume":"583","author":"C Amor","year":"2020","unstructured":"Amor C, Feucht J, Leibold J, et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature. 2020;583(7814):127\u201332. https:\/\/doi.org\/10.1038\/s41586-020-2403-9.","journal-title":"Nature"},{"issue":"7","key":"1759_CR107","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14203","volume":"54","author":"D Ramoni","year":"2024","unstructured":"Ramoni D, Montecucco F, Carbone F. CAR t therapy from haematological malignancies to aging-related diseases: an ever-expanding universe. Eur J Clin Invest. 2024;54(7):e14203. https:\/\/doi.org\/10.1111\/eci.14203.","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"1759_CR108","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.medj.2024.03.016","volume":"5","author":"J Shu","year":"2024","unstructured":"Shu J, Xie W, Chen Z, Offringa R, Hu Y, Mei H. The enchanting canvas of CAR technology: unveiling its wonders in non-neoplastic diseases. Med. 2024;5(6):495\u2013529. https:\/\/doi.org\/10.1016\/j.medj.2024.03.016.","journal-title":"Med"},{"issue":"7","key":"1759_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102209","volume":"6","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Ma B, Li B, et al. Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging. Cell Rep Med. 2025;102209. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102209.","journal-title":"Cell Rep Med"},{"key":"1759_CR110","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jconrel.2023.07.021","volume":"360","author":"Z Yang","year":"2023","unstructured":"Yang Z, Liu Y, Zhao K, et al. Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy. J Control Release. 2023;360:718\u201333. https:\/\/doi.org\/10.1016\/j.jconrel.2023.07.021.","journal-title":"J Control Release"},{"issue":"2","key":"1759_CR111","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1046\/j.1365-3083.1996.d01-297.x","volume":"44","author":"U Kubicka","year":"1996","unstructured":"Kubicka U, Olszewski WL, Tarnowski W, Bielecki K, Zi\u00f3\u0142kowska A, Wierzbicki Z. Normal human immune peritoneal cells: subpopulations and functional characteristics. Scand J Immunol. 1996;44(2):157\u201363. https:\/\/doi.org\/10.1046\/j.1365-3083.1996.d01-297.x.","journal-title":"Scand J Immunol"},{"key":"1759_CR112","doi-asserted-by":"crossref","unstructured":"Gu K, Liang T, Hu L et al. Intraperitoneal programming of tailored CAR macrophages via mRNA-LNP to boost cancer immunotherapy. BioRxiv 2024.","DOI":"10.1101\/2024.07.30.605730"},{"key":"1759_CR113","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202312038","author":"AJ Mukalel","year":"2024","unstructured":"Mukalel AJ, Hamilton AG, Billingsley MM, et al. Oxidized mRNA lipid nanoparticles for in situ chimeric antigen receptor monocyte engineering. Adv Funct Mater. 2024. https:\/\/doi.org\/10.1002\/adfm.202312038.","journal-title":"Adv Funct Mater"},{"issue":"12","key":"1759_CR114","doi-asserted-by":"publisher","first-page":"e2006484","DOI":"10.1002\/smll.202006484","volume":"17","author":"F Oroojalian","year":"2021","unstructured":"Oroojalian F, Beygi M, Baradaran B, Mokhtarzadeh A, Shahbazi MA. Immune cell Membrane-Coated biomimetic nanoparticles for targeted cancer therapy. Small. 2021;17(12):e2006484. https:\/\/doi.org\/10.1002\/smll.202006484.","journal-title":"Small"},{"key":"1759_CR115","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.actbio.2023.11.029","volume":"174","author":"S Li","year":"2024","unstructured":"Li S, Meng X, Peng B, et al. Cell membrane-based biomimetic technology for cancer phototherapy: mechanisms, recent advances and perspectives. Acta Biomater. 2024;174:26\u201348. https:\/\/doi.org\/10.1016\/j.actbio.2023.11.029.","journal-title":"Acta Biomater"},{"issue":"7","key":"1759_CR116","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.7150\/thno.52570","volume":"11","author":"Y Liang","year":"2021","unstructured":"Liang Y, Duan L, Lu J, Xia J. Engineering exosomes for targeted drug delivery. Theranostics. 2021;11(7):3183\u201395. https:\/\/doi.org\/10.7150\/thno.52570.","journal-title":"Theranostics"},{"issue":"9","key":"1759_CR117","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1080\/17425247.2020.1783235","volume":"17","author":"Q Tong","year":"2020","unstructured":"Tong Q, Qiu N, Ji J, Ye L, Zhai G. Research progress in bioinspired drug delivery systems. Expert Opin Drug Deliv. 2020;17(9):1269\u201388. https:\/\/doi.org\/10.1080\/17425247.2020.1783235.","journal-title":"Expert Opin Drug Deliv"},{"issue":"15","key":"1759_CR118","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1039\/c9tb00170k","volume":"7","author":"M Zhang","year":"2019","unstructured":"Zhang M, Zang X, Wang M, et al. Exosome-based nanocarriers as bio-inspired and versatile vehicles for drug delivery: recent advances and challenges. J Mater Chem B. 2019;7(15):2421\u201333. https:\/\/doi.org\/10.1039\/c9tb00170k.","journal-title":"J Mater Chem B"},{"issue":"7","key":"1759_CR119","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1080\/09537104.2018.1475633","volume":"29","author":"S Wang","year":"2018","unstructured":"Wang S, Yuan J, Yang J, et al. Advancement of platelet-inspired nanomedicine. Platelets. 2018;29(7):690\u20134. https:\/\/doi.org\/10.1080\/09537104.2018.1475633.","journal-title":"Platelets"},{"key":"1759_CR120","unstructured":"Xiaoyan Wu ZH. Inventor use of gene editing system having biomimetic platelet function for inducing CAR-T cell in vivo to target and treat tumors. China. 2024."},{"issue":"5","key":"1759_CR121","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/adhm.201200138","volume":"1","author":"CM Hu","year":"2012","unstructured":"Hu CM, Fang RH, Zhang L. Erythrocyte-inspired delivery systems. Adv Healthc Mater. 2012;1(5):537\u201347. https:\/\/doi.org\/10.1002\/adhm.201200138.","journal-title":"Adv Healthc Mater"},{"issue":"8","key":"1759_CR122","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1517\/17425247.2014.927436","volume":"11","author":"M Bhateria","year":"2014","unstructured":"Bhateria M, Rachumallu R, Singh R, Bhatta RS. Erythrocytes-based synthetic delivery systems: transition from conventional to novel engineering strategies. Expert Opin Drug Deliv. 2014;11(8):1219\u201336. https:\/\/doi.org\/10.1517\/17425247.2014.927436.","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"1759_CR123","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.transci.2016.10.017","volume":"55","author":"CH Villa","year":"2016","unstructured":"Villa CH, Seghatchian J, Muzykantov V. Drug delivery by erythrocytes: primum non nocere. Transfus Apher Sci. 2016;55(3):275\u201380. https:\/\/doi.org\/10.1016\/j.transci.2016.10.017.","journal-title":"Transfus Apher Sci"},{"key":"1759_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.celbio.2025.100143","volume":"1","author":"T Pan","year":"2025","unstructured":"Pan T, Yang C-H, Zhao K, et al. Biomimetic artificial enveloped viral vectors: overcoming immune barriers for re-administration and long-term gene therapy. Cell Biomater. 2025;1:100143. https:\/\/doi.org\/10.1016\/j.celbio.2025.100143.","journal-title":"Cell Biomater"},{"issue":"7","key":"1759_CR125","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/s41551-021-00815-9","volume":"6","author":"H Wang","year":"2022","unstructured":"Wang H, Alarc\u00f3n CN, Liu B, et al. Genetically engineered and enucleated human mesenchymal stromal cells for the targeted delivery of therapeutics to diseased tissue. Nat Biomed Eng. 2022;6(7):882\u201397. https:\/\/doi.org\/10.1038\/s41551-021-00815-9.","journal-title":"Nat Biomed Eng"},{"issue":"45","key":"1759_CR126","doi-asserted-by":"publisher","first-page":"e2412253","DOI":"10.1002\/adma.202412253","volume":"36","author":"Z Chen","year":"2024","unstructured":"Chen Z, Zou Y, Sun H, et al. Engineered enucleated mesenchymal stem cells regulating immune microenvironment and promoting wound healing. Adv Mater. 2024;36(45):e2412253. https:\/\/doi.org\/10.1002\/adma.202412253.","journal-title":"Adv Mater"},{"issue":"29","key":"1759_CR127","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2426724122","volume":"122","author":"L Zhou","year":"2025","unstructured":"Zhou L, Song Q, Zhang X, et al. In vivo generation of CAR macrophages via the enucleated mesenchymal stem cell delivery system for glioblastoma therapy. Proc Natl Acad Sci U S A. 2025;122(29):e2426724122. https:\/\/doi.org\/10.1073\/pnas.2426724122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1759_CR128","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.scib.2023.11.055","volume":"69","author":"Z Gui","year":"2024","unstructured":"Gui Z, Yue Z, Cong-Fei X, Jun W. In vivo production of CAR-T cells using virus-mimetic fusogenic nanovesicles. Sci Bull (Beijing). 2024;69(3):354\u201366. https:\/\/doi.org\/10.1016\/j.scib.2023.11.055.","journal-title":"Sci Bull (Beijing)"},{"key":"1759_CR129","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.eng.2021.10.021","volume":"13","author":"W Liu","year":"2022","unstructured":"Liu W, Wang Y, Wang J, et al. Macroencapsulation devices for cell therapy. Engineering. 2022;13:53\u201370. https:\/\/doi.org\/10.1016\/j.eng.2021.10.021.","journal-title":"Engineering"},{"issue":"16","key":"1759_CR130","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202100820","volume":"8","author":"D Goswami","year":"2021","unstructured":"Goswami D, Domingo-Lopez DA, Ward NA, et al. Design considerations for macroencapsulation devices for stem cell derived islets for the treatment of type 1 diabetes. Adv Sci. 2021;8(16):e2100820. https:\/\/doi.org\/10.1002\/advs.202100820.","journal-title":"Adv Sci"},{"key":"1759_CR131","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/978-1-0716-0215-7_32","volume":"2100","author":"E Santos-Vizcaino","year":"2020","unstructured":"Santos-Vizcaino E, Orive G, Pedraz JL, Hernandez RM. Clinical applications of cell encapsulation technology. Methods Mol Biol. 2020;2100:473\u201391. https:\/\/doi.org\/10.1007\/978-1-0716-0215-7_32.","journal-title":"Methods Mol Biol"},{"issue":"8","key":"1759_CR132","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41587-022-01245-x","volume":"40","author":"P Agarwalla","year":"2022","unstructured":"Agarwalla P, Ogunnaike EA, Ahn S, et al. Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells. Nat Biotechnol. 2022;40(8):1250\u20138. https:\/\/doi.org\/10.1038\/s41587-022-01245-x.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"1759_CR133","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00830-x","volume":"6","author":"H Cao","year":"2021","unstructured":"Cao H, Duan L, Zhang Y, Cao J, Zhang K. Current hydrogel advances in physicochemical and biological response-driven biomedical application diversity. Signal Transduct Target Ther. 2021;6(1):426. https:\/\/doi.org\/10.1038\/s41392-021-00830-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"1759_CR134","doi-asserted-by":"publisher","first-page":"e2310078","DOI":"10.1002\/adma.202310078","volume":"36","author":"C Zhu","year":"2024","unstructured":"Zhu C, Ke L, Ao X, et al. Injectable supramolecular hydrogels for in situ programming of Car-T cells toward solid tumor immunotherapy. Adv Mater. 2024;36(5):e2310078. https:\/\/doi.org\/10.1002\/adma.202310078.","journal-title":"Adv Mater"},{"issue":"1","key":"1759_CR135","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00506-6","volume":"6","author":"Z Duan","year":"2021","unstructured":"Duan Z, Luo Y. Targeting macrophages in cancer immunotherapy. Signal Transduct Target Ther. 2021;6(1):127. https:\/\/doi.org\/10.1038\/s41392-021-00506-6.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"1759_CR136","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ni.1937","volume":"11","author":"SK Biswas","year":"2010","unstructured":"Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889\u201396. https:\/\/doi.org\/10.1038\/ni.1937.","journal-title":"Nat Immunol"},{"issue":"656","key":"1759_CR137","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn1128","volume":"14","author":"C Chen","year":"2022","unstructured":"Chen C, Jing W, Chen Y, et al. Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy. Sci Transl Med. 2022;14(656):eabn1128. https:\/\/doi.org\/10.1126\/scitranslmed.abn1128.","journal-title":"Sci Transl Med"},{"issue":"5","key":"1759_CR138","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s43018-025-00950-1","volume":"6","author":"W Jing","year":"2025","unstructured":"Jing W, Han M, Wang G, et al. An in situ engineered chimeric IL-2 receptor potentiates the tumoricidal activity of proinflammatory CAR macrophages in renal cell carcinoma. Nat Cancer. 2025;6(5):838\u201353. https:\/\/doi.org\/10.1038\/s43018-025-00950-1.","journal-title":"Nat Cancer"},{"key":"1759_CR139","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006292","author":"KR Michels","year":"2023","unstructured":"Michels KR, Sheih A, Hernandez SA, et al. Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2022-006292.","journal-title":"J Immunother Cancer"},{"issue":"Supplement 1","key":"1759_CR140","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1182\/blood-2024-211032","volume":"144","author":"AH Brandes","year":"2024","unstructured":"Brandes AH, Koo ASM, Perez A, et al. Nonclinical toxicology, biodistribution, and pharmacokinetics of UB-VV111, an in vivo anti-CD19 CAR T cell therapy. Blood. 2024;144(Supplement 1):2046. https:\/\/doi.org\/10.1182\/blood-2024-211032.","journal-title":"Blood"},{"key":"1759_CR141","doi-asserted-by":"publisher","unstructured":"Xin-Feng C, Ke H, Jin-Yan L, et al. 1482 In-vivo CAR-T cells produced by specific virus in refractory B cell lymphoma. J Immunother Cancer. 2024;12(Suppl 3). https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.1482.","DOI":"10.1136\/jitc-2024-SITC2024.1482"},{"issue":"6Supplement","key":"1759_CR142","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1158\/1538-7445.AM2024-48","volume":"84","author":"ET Beura","year":"2024","unstructured":"Beura ET, Latimer HJ, Wong D, et al. Abstract 48: T cell-specific in vivo transduction with preclinical candidate KLN-1010 generates BCMA directed CAR T cells with potent anti-multiple myeloma activity. Cancer Res. 2024;84(6Supplement):48. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-48.","journal-title":"Cancer Res"},{"key":"1759_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01030-X","author":"J Xu","year":"2025","unstructured":"Xu J, Liu L, Parone P. In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma. Lancet. 2025. https:\/\/doi.org\/10.1016\/S0140-6736(25)01030-X.","journal-title":"Lancet"},{"issue":"16suppl","key":"1759_CR144","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1200\/JCO.2025.43.16_suppl.2591","volume":"43","author":"CR Lemech","year":"2025","unstructured":"Lemech CR, Cosman R, Humphries TG, et al. First-in-human mRNA CAR therapy: correlative biomarker analysis from the MT-302 phase 1 study targeting TROP2 in patients with advanced epithelial tumors. J Clin Oncol. 2025;43(16suppl):2591. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.2591.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"1759_CR145","doi-asserted-by":"publisher","first-page":"TPS4218","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS4218","volume":"43","author":"TG Humphries","year":"2025","unstructured":"Humphries TG, Roberts SK, Sim H-W, et al. A first-in-human study of MT-303, an innovative in vivo mRNA chimeric antigen receptor (CAR) therapy targeting GPC3, in adults with hepatocellular carcinoma. J Clin Oncol. 2025;43(16suppl):TPS4218-TPS. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.TPS4218.","journal-title":"J Clin Oncol"},{"key":"1759_CR146","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2509522","author":"Q Wang","year":"2025","unstructured":"Wang Q, Xiao ZX, Zheng X, et al. In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMc2509522.","journal-title":"N Engl J Med"},{"issue":"3","key":"1759_CR147","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","volume":"28","author":"H Costa Verdera","year":"2020","unstructured":"Costa Verdera H, Kuranda K, Mingozzi F. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol Ther. 2020;28(3):723\u201346. https:\/\/doi.org\/10.1016\/j.ymthe.2019.12.010.","journal-title":"Mol Ther"},{"issue":"3","key":"1759_CR148","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ymthe.2023.01.010","volume":"31","author":"M Schulz","year":"2023","unstructured":"Schulz M, Levy DI, Petropoulos CJ, et al. Binding and neutralizing anti-AAV antibodies: detection and implications for rAAV-mediated gene therapy. Mol Ther. 2023;31(3):616\u201330. https:\/\/doi.org\/10.1016\/j.ymthe.2023.01.010.","journal-title":"Mol Ther"},{"issue":"11","key":"1759_CR149","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.15252\/emmm.201708148","volume":"9","author":"M Milani","year":"2017","unstructured":"Milani M, Annoni A, Bartolaccini S, et al. Genome editing for scalable production of alloantigen-free lentiviral vectors for in vivo gene therapy. EMBO Mol Med. 2017;9(11):1558\u201373. https:\/\/doi.org\/10.15252\/emmm.201708148.","journal-title":"EMBO Mol Med"},{"key":"1759_CR150","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav7325","author":"M Milani","year":"2019","unstructured":"Milani M, Annoni A, Moalli F, et al. Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates. Sci Transl Med. 2019. https:\/\/doi.org\/10.1126\/scitranslmed.aav7325.","journal-title":"Sci Transl Med"},{"issue":"2","key":"1759_CR151","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2174\/1566523214666140302193709","volume":"14","author":"B Balakrishnan","year":"2014","unstructured":"Balakrishnan B, Jayandharan GR. Basic biology of adeno-associated virus (AAV) vectors used in gene therapy. Curr Gene Ther. 2014;14(2):86\u2013100. https:\/\/doi.org\/10.2174\/1566523214666140302193709.","journal-title":"Curr Gene Ther"},{"issue":"35","key":"1759_CR152","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202303215","volume":"10","author":"Z Chen","year":"2023","unstructured":"Chen Z, Hu Y, Mei H. Advances in CAR-engineered immune cell generation: engineering approaches and sourcing strategies. Adv Sci. 2023;10(35):e2303215. https:\/\/doi.org\/10.1002\/advs.202303215.","journal-title":"Adv Sci"},{"issue":"1","key":"1759_CR153","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00434-9","volume":"10","author":"Y Liu","year":"2022","unstructured":"Liu Y, An L, Huang R, et al. Strategies to enhance CAR-T persistence. Biomark Res. 2022;10(1):86. https:\/\/doi.org\/10.1186\/s40364-022-00434-9.","journal-title":"Biomark Res"},{"issue":"9","key":"1759_CR154","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","volume":"6","author":"S Ghassemi","year":"2018","unstructured":"Ghassemi S, Nunez-Cruz S, O\u2019Connor RS, et al. Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells. Cancer Immunol Res. 2018;6(9):1100\u20139. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0405.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1759_CR155","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","volume":"38","author":"C Li","year":"2024","unstructured":"Li C, Xu J, Luo W, et al. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma. Leukemia. 2024;38(1):149\u201359. https:\/\/doi.org\/10.1038\/s41375-023-02065-x.","journal-title":"Leukemia"},{"issue":"1","key":"1759_CR156","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda SM. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Rev Clin Oncol. 2024;21(1):47\u201366. https:\/\/doi.org\/10.1038\/s41571-023-00832-4.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"1759_CR157","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/mt.2009.282","volume":"18","author":"GD Trobridge","year":"2010","unstructured":"Trobridge GD, Wu RA, Hansen M, et al. Cocal-pseudotyped lentiviral vectors resist inactivation by human serum and efficiently transduce primate hematopoietic repopulating cells. Mol Ther. 2010;18(4):725\u201333. https:\/\/doi.org\/10.1038\/mt.2009.282.","journal-title":"Mol Ther"},{"issue":"1","key":"1759_CR158","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-03179-5","volume":"43","author":"A Krug","year":"2024","unstructured":"Krug A, Saidane A, Martinello C, et al. In vivo CAR T cell therapy against angioimmunoblastic T cell lymphoma. J Exp Clin Cancer Res. 2024;43(1):262. https:\/\/doi.org\/10.1186\/s13046-024-03179-5.","journal-title":"J Exp Clin Cancer Res"},{"key":"1759_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.03.041","author":"L Labanieh","year":"2022","unstructured":"Labanieh L, Majzner RG, Klysz D, et al. Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell. 2022. https:\/\/doi.org\/10.1016\/j.cell.2022.03.041.","journal-title":"Cell"},{"issue":"12","key":"1759_CR160","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202205044","volume":"10","author":"X Wang","year":"2023","unstructured":"Wang X, Meng F, Li X, et al. Nanomodified switch induced precise and moderate activation of CAR-T cells for solid tumors. Adv Sci. 2023;10(12):e2205044. https:\/\/doi.org\/10.1002\/advs.202205044.","journal-title":"Adv Sci"},{"key":"1759_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115419","volume":"213","author":"AG Lokras","year":"2024","unstructured":"Lokras AG, Bobak TR, Baghel SS, Sebastiani F, Foged C. Advances in the design and delivery of RNA vaccines for infectious diseases. Adv Drug Deliv Rev. 2024;213:115419. https:\/\/doi.org\/10.1016\/j.addr.2024.115419.","journal-title":"Adv Drug Deliv Rev"},{"issue":"24","key":"1759_CR162","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2504950122","volume":"122","author":"N Zhang","year":"2025","unstructured":"Zhang N, Seo JW, Robinson E, et al. Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging. Proc Natl Acad Sci U S A. 2025;122(24):e2504950122. https:\/\/doi.org\/10.1073\/pnas.2504950122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1759_CR163","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1056\/NEJMoa2411507","volume":"392","author":"K Perica","year":"2025","unstructured":"Perica K, Jain N, Scordo M, et al. CD4\u2009+\u2009T-cell lymphoma harboring a chimeric antigen receptor integration in TP53. N Engl J Med. 2025;392(6):577\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2411507.","journal-title":"N Engl J Med"},{"issue":"4","key":"1759_CR164","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi G, Fraietta JA, Gerson JN, et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med. 2024;30(4):984\u20139. https:\/\/doi.org\/10.1038\/s41591-024-02826-w.","journal-title":"Nat Med"},{"issue":"13","key":"1759_CR165","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa2402730","volume":"391","author":"G Kobbe","year":"2024","unstructured":"Kobbe G, Br\u00fcggemann M, Baermann B-N, et al. Aggressive lymphoma after CD19 CAR T-cell therapy. N Engl J Med. 2024;391(13):1217\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2402730.","journal-title":"N Engl J Med"},{"issue":"7","key":"1759_CR166","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1056\/NEJMoa2309728","volume":"392","author":"SJ Harrison","year":"2025","unstructured":"Harrison SJ, Touzeau C, Kint N, et al. CAR\u2009+\u2009T-Cell lymphoma after Cilta-cel therapy for relapsed or refractory myeloma. N Engl J Med. 2025;392(7):677\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2309728.","journal-title":"N Engl J Med"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01759-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01759-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01759-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T01:19:57Z","timestamp":1763601597000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01759-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":166,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1759"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01759-2","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"3 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}